RxDoctor Payments DataLook up a doctor →

Wilma Baliem

Nurse Practitioner · Mobile, ALNPI 1871706978

Payments from drug & device makers

$12,753in general payments, 2019–2025

Across 642 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Incyte Corporation$812
  • Regeneron Healthcare Solutions, Inc.$783
  • Daiichi Sankyo Inc.$685
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis68$1,215
Johnson & Johnson70$1,214
AstraZeneca(2 entities)46$1,080
Incyte Corporation36$812
Regeneron Healthcare Solutions, Inc.35$783
Daiichi Sankyo Inc.32$685
Eisai Inc.38$634
Stemline Therapeutics Inc.14$572
Bristol Myers Squibb22$508
Merck28$469
Pharmacosmos Therapeutics Inc.9$365
Sanofi19$337
Pfizer19$327
Amgen19$281
AbbVie11$258
Takeda Pharmaceuticals U.S.A., Inc.10$253
Lilly USA, LLC10$239
Sobi, Inc10$167
Genentech USA, Inc.10$165
Bayer8$141
Pharmaessentia USA Corporation7$139
Array Biopharma Inc9$138
Tersera Therapeutics LLC6$137
GSK8$132
Exelixis Inc.7$132
Genmab U.S., Inc.7$110
Beigene USA, Inc.6$108
Blueprint Medicines Corporation5$99
Gilead(2 entities)5$91
Taiho Oncology, Inc.5$90
EMD Serono, Inc.4$88
Astellas Pharma US Inc5$81
Immunocore Limited3$66
Sumitomo Pharma America, Inc.1$61
Seagen Inc.4$61
ADC Therapeutics America, Inc.3$55
Mirati Therapeutics, Inc.3$50
Epizyme, Inc.3$47
Puma Biotechnology, Inc.3$45
Dendreon Pharmaceuticals LLC2$38
Boehringer Ingelheim2$37
Myovant Sciences Inc.3$36
Immunogen, Inc.2$32
Beone Medicines USA, Inc.2$31
AVEO Pharmaceuticals, Inc.2$31
Morphosys, US Inc.2$30
E.r. Squibb & Sons, L.L.C.2$30
Servier Pharmaceuticals LLC2$29
Karyopharm Therapeutics Inc.2$27
Novocure Inc.1$24
Ipsen Biopharmaceuticals, Inc1$19
Corcept Therapeutics1$17
Caris MPI, Inc.1$17
Agios Pharmaceuticals, Inc.1$16
Rigel Pharmaceuticals, Inc.1$16
Apellis Pharmaceuticals, Inc.1$15
Myriad Genetic Laboratories, Inc.1$14
Cumberland Pharmaceuticals, Inc.1$14
Springworks Therapeutics, Inc.1$14
Spectrum Pharmaceuticals Inc.1$13

How this compares

$12,753 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama →

Medicare billing

Part B allowed, 2024
$7,557
Medicare patients
72
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →